Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Common Equity: 2016-2025

Historic Common Equity for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $9.2 million.

  • Ultragenyx Pharmaceutical's Common Equity fell 97.36% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 97.36%. This contributed to the annual value of $255.3 million for FY2024, which is 7.30% down from last year.
  • Ultragenyx Pharmaceutical's Common Equity amounted to $9.2 million in Q3 2025, which was down 93.95% from $151.3 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Common Equity's 5-year high stood at $1.1 billion during Q1 2021, with a 5-year trough of $9.2 million in Q3 2025.
  • Its 3-year average for Common Equity is $194.2 million, with a median of $151.3 million in 2025.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Common Equity spiked by 993.61% in 2024, and later crashed by 97.36% in 2025.
  • Ultragenyx Pharmaceutical's Common Equity (Quarterly) stood at $922.6 million in 2021, then slumped by 61.79% to $352.5 million in 2022, then decreased by 21.87% to $275.4 million in 2023, then decreased by 7.30% to $255.3 million in 2024, then crashed by 97.36% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $151.3 million for Q2 2025, and $144.2 million during Q1 2025.